Repligen (RGEN) Expected to Post Earnings on Tuesday

Repligen (NASDAQ:RGEN) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect Repligen to announce earnings of $0.4628 per share and revenue of $206.71 million for the quarter. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter in the prior year, the business posted $0.26 EPS. Repligen’s quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts expect Repligen to post $2.06 EPS for the current fiscal year and $2.59 EPS for the next fiscal year.

Repligen Stock Performance

Shares of RGEN stock opened at $176.93 on Monday. The business’s 50 day moving average is $177.12 and its two-hundred day moving average is $147.88. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $100.99 and a 12 month high of $198.87. The company has a market cap of $9.99 billion, a PE ratio of 242.37, a price-to-earnings-growth ratio of 3.23 and a beta of 1.08.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on RGEN shares. Wells Fargo & Company lifted their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Finally, Evercore reissued an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average price target of $175.71.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.